Calidi Biotherapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Calidi Biotherapeutics Inc.
- Former names
- First Light Acquisition Group, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2836 — Biological Products, (No Diagnostic Substances)
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- CLDI
- Primary stock exchange
- NYSE American
Identifiers
- SEC CIK
- 0001855485
- EIN
- 86-2967193
Board of directors
-
Alan R. Stewart · DirectorSince 2023
-
Alfonso G. Zulueta · DirectorSince 2024
-
Allan Camaisa · Director · CEO and Chairman of the BoardSince 2023
-
Corazon (Corsee) D. Sanders · DirectorSince 2026
-
David LaPre · DirectorSince 2024
-
Eric E. Poma · Director · Chief Executive OfficerSince 2025
-
George K. Ng · DirectorSince 2023
-
George Peoples · DirectorSince 2024
-
Heehyoung Lee · DirectorSince 2023
-
James A. Schoeneck · DirectorSince 2023
-
Scott Leftwich · DirectorSince 2023
-
Thomas A. Vecchiolla · DirectorSince 2023
Chief executives
Eric E. Poma
· Chief Executive Officer
Dates unknown
Allan Camaisa
· CEO, President and Chairman
Since September 2023
Director election results
Annual meeting of July 9, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
84.9%
-
86.4%
Board connections
4 of this board's directors also sit on 8 other boards.
- via Corazon (Corsee) D. Sanders
- via Alfonso G. Zulueta
- via James A. Schoeneck
- via James A. Schoeneck
- via Corazon (Corsee) D. Sanders
- via George K. Ng
- via George K. Ng
- via Corazon (Corsee) D. Sanders
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $1,241
- 1 sale by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Dec 12, 2025 | Allan Camaisa Director | Open-market sale | −850 | $1.46 | $1,241 |
| Aug 21, 2025 | Jackson Andrew C. Officer (Chief Financial Officer) | Open-market purchase | +2,500 | $2.00 | $5,000 |
| Aug 21, 2025 | Scott Leftwich Director | Open-market purchase | +125,000 | $2.00 | $250,000 |
| Aug 21, 2025 | Eric E. Poma Director, Officer (Chief Executive Officer) | Open-market purchase | +25,000 | $2.00 | $50,000 |
| Aug 21, 2025 | James A. Schoeneck Director | Open-market purchase | +75,000 | $2.00 | $150,000 |
| Dec 31, 2024 | Alan R. Stewart Director | Grant or award | +12,771 | — | — |
| Dec 31, 2024 | Scott Leftwich Director | Grant or award | +11,684 | — | — |
| Dec 17, 2024 | Allan Camaisa Director, Officer (CEO and Chairman of the Board) | Open-market sale | −10,000 | $1.62 | $16,200 |
| Sep 26, 2024 | Allan Camaisa Director, Officer (CEO and Chairman of the Board), 10% owner | Grant or award | +70,155 | $1.15 | $80,678 |
| Jun 28, 2024 | Scott Leftwich Director | Grant or award | +67,187 | — | — |
| Jun 28, 2024 | James A. Schoeneck Director | Grant or award | +79,687 | — | — |
| Jun 28, 2024 | Alan R. Stewart Director | Grant or award | +73,437 | — | — |
| Jun 3, 2024 | James A. Schoeneck Director | Option exercise | +173,000 | $0.20 | $34,600 |
| Jun 3, 2024 | James A. Schoeneck Director | Option exercise | +375,000 | $0.20 | $75,000 |
| Apr 18, 2024 | James A. Schoeneck Director | Grant or award | +375,000 | $0.40 | $150,000 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.